The Official MicroCap News Source
Watchlist News
Please Login or Register to view News Stories

Healthcare & Insurance

Zealand Pharma completes the acquisition of Valeritas

Company announcement – No. 15 / 2020 Zealand Pharma completes the acquisition of Valeritas Zealand Pharma (NASDAQ: ZEAL) has acquired Valeritas Holdings, Inc. (NASDAQ: VLRX), a U.S. based commercial-stage company for a cash purchase price of $23 million The marketed V-Go® wearable insulin

Thursday, April 02, 2020

RETRANSMISSION - PREMIER HEALTH OF AMERICA INC. COVID-19 BUSINESS UPDATE

MONTREAL, April 02, 2020 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (formerly known as Physinorth Acquisition Corporation Inc.) (TSXV: PHA)) (the “Corporation”) wishes to provide a business update in relation with the recent evolution of the Covid-19 situation. Current situation

Thursday, April 02, 2020

RETRANSMISSION - PREMIER HEALTHCARE OF AMERICA ANNOUNCES THAT ITS SUBSIDIARY EXCEL SANTÉ INC. WAS SELECTED BY THE PROVINCIAL GOVERNMENT

MONTREAL, April 02, 2020 (GLOBE NEWSWIRE) -- Premier Healthcare of America (the "Company" or "PHA") is pleased to announce that its subsidiary Excel Santé Inc. ("Excel") has been selected by the Quebec Côte-Nord CISSS ("CISSS") for the issuance of a standing offer for temporary nursing

Thursday, April 02, 2020

La Jolla Pharmaceutical Company to Provide GIAPREZA™ (Angiotensin II) for Named Patient Emergency Use in Patients with Septic Shock Due to COVID-19

SAN DIEGO, April 02, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it is providing

Thursday, April 02, 2020

Fluidigm CyTOF Technology Used to Evaluate Stem Cell Therapy as a Potential Treatment for COVID-19 Pneumonia

SOUTH SAN FRANCISCO, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Fluidigm® CyTOF® technology was used in a clinical study

Thursday, April 02, 2020

Aesthetic Medical International Holdings Group Limited Enters into Definitive Agreements to Acquire Controlling Interest in Two Treatment Centers

Shenzhen, April 02, 2020 (GLOBE NEWSWIRE) -- Aesthetic Medical International Holdings Group Limited (the “Company” or Nasdaq: AIH), a leading provider of aesthetic medical services in China, today announced the Company, through its affiliates, entered into definitive agreements (the

Thursday, April 02, 2020

Algernon Provides Update on Phase 2 Human Testing of Ifenprodil for COVID-19

VANCOUVER, British Columbia, April 02, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that the protocol for a planned physician

Thursday, April 02, 2020

InsuraGuest Technologies Spotlighted in Broadcast Discussing Insurtech’s Indelible Impact on Insurance Sector

NEW YORK, April 02, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – InsuraGuest Technologies Inc. (TSX.V: ISGI) announces the availability of a broadcast titled, “Technology Transforms the Insurance Market.” To hear the AudioPressRelease from NetworkNewsAudio, visit: http://nnw.fm/5GVQu

Thursday, April 02, 2020

Galectin Therapeutics Update on the Impact of COVID-19

NORCROSS, Ga., April 02, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins today provided an update on the impact of the COVID-19 pandemic on the Company and its clinical trial activities. As the global

Thursday, April 02, 2020

Crown Bioscience Expands PDX Collection with Acquisition of Unique Models from Leading Academic Medical Centers

Agreements with CoMotion at the University of Washington and Dana-Farber Cancer Institute add new prostate cancer and lymphoma models to the world’s largest PDX collectionSAN DIEGO, April 02, 2020 (GLOBE NEWSWIRE) -- Crown Bioscience today announced the strategic expansion of their PDX

Thursday, April 02, 2020

Nova Leap Health Corp. Announces Organic Expansion to the State of Ohio

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, April 02, 2020 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a 2019 TSX Venture 50™ ranked company focused on the home health care

Thursday, April 02, 2020

VigiLanz® Announces Precision Dosing Powered by Tabula Rasa HealthCare’s DoseMeRx™

DoseMeRx to integrate with VigiLanz clinical surveillance solutions for hospitalsMOORESTOWN, N.J., April 02, 2020 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc® (TRHC) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, has partnered with VigiLanz®, the

Thursday, April 02, 2020

Spectral Provides Update on the Commercial Development of its SAMI Device for Continuous Renal Replacement Therapy

Two new hospitals in Canada and the U.S. place orders for SAMITORONTO, April 02, 2020 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, is pleased to provide an

Thursday, April 02, 2020

Galera Therapeutics Appoints Linda B. West to Board of Directors

MALVERN, Pa., April 02, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today

Thursday, April 02, 2020

ALIGN TECHNOLOGY COMPLETES ACQUISITION OF EXOCAD, A GLOBAL DENTAL CAD/CAM SOFTWARE LEADER

SAN JOSE, Calif. and DARMSTADT, Germany, April 02, 2020 (GLOBE NEWSWIRE) -- Align Technology, Inc. (Align) (Nasdaq: ALGN) today announced that it has completed the acquisition of privately-held exocad Global Holdings GmbH (exocad), a global leader in the dental CAD/CAM software market that offers

Thursday, April 02, 2020

Menlo Announces Settlement to Conclude Finacea Foam Litigation and Announces that Partner, LEO Pharma A/S, Remedies Finacea Foam Supply Issues

BRIDGEWATER, N.J., April 02, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that its

Thursday, April 02, 2020

Eve & Co Commences Canadian Medical Sales through Cannalogue

STRATHROY, Ontario, April 02, 2020 (GLOBE NEWSWIRE) -- Eve & Co Incorporated (“Eve & Co” or the “Company”) (TSX-V: EVE; QTCQX: EEVVF) is pleased to announce that it has, through its wholly-owned subsidiary Natural MedCo Ltd., entered the Canadian medical cannabis market through

Thursday, April 02, 2020

Spring Bank Provides Update on Business Operations & Clinical Program Progress During COVID-19 Pandemic

Pursuing collaborations to develop internal compounds for potential treatment of COVID-19Safety Review Committee for IV SB 11285 Phase 1a/1b trial recommends dose escalation to next planned dose level; initial patient dosed in next cohortClinical abstracts for IV SB 11285 Phase 1a/1b trial accepted

Thursday, April 02, 2020

Intra-Cellular Therapies Initiates Promotional Activities for CAPLYTA™ (lumateperone) for the Treatment of Schizophrenia in Adults

Intra-Cellular Therapies launches LYTAlink™, a comprehensive patient affordability and access program for CAPLYTANEW YORK, April 02, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of

Thursday, April 02, 2020

Tetra Bio-Pharma Maps Out Cannabinoid Metabolites in Humans Following Inhalation of QIXLEEF

Bioanalytical methods developed and validated for its clinical trials. Tetra initiates study to quantify phytocannabinoid metabolites and precursors and minor phytocannabinoids in human plasma. OTTAWA, April 02, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”)

Thursday, April 02, 2020

loading

© 2020 Stock News Now